Karyopharm Therapeutics, Inc. (KPTI) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Zevra Therapeutics, Inc.

XOMA Corp.

Emergent BioSolutions, Inc.

Applied Therapeutics, Inc.

Alimera Sciences, Inc.

Zomedica Corp.

Atara Biotherapeutics, Inc.

Karyopharm Therapeutics, Inc.

Sagimet Biosciences, Inc.

PDS Biotechnology Corp.

Actinium Pharmaceuticals, Inc.

Why is Karyopharm Therapeutics, Inc. ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate 8.04% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -4.72

Flat results in Dec 25

CASH AND EQV(HY) Lowest at USD 109.62 MM
INTEREST(Q) Highest at USD 12.62 MM
PRE-TAX PROFIT(Q) Lowest at USD -39.9 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 30.87%, its profits have fallen by -10.5%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Karyopharm Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Karyopharm Therapeutics, Inc.

3.74%

-0.47

100.46%

S&P 500

16.12%

0.77

19.29%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

6.21%

EBIT Growth (5y)

8.04%

EBIT to Interest (avg)

-4.72

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.54

Sales to Capital Employed (avg)

10.63

Tax Ratio

0.04%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

40.76%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.54

EV to EBIT

-3.54

EV to EBITDA

-3.55

EV to Capital Employed

-2.49

EV to Sales

2.20

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -75.37 MM

NET PROFIT(HY)

Higher at USD -72.96 MM

RAW MATERIAL COST(Y)

Fallen by -0.22% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 5.13 times

-11What is not working for the Company

CASH AND EQV(HY)

Lowest at USD 109.62 MM

INTEREST(Q)

Highest at USD 12.62 MM

PRE-TAX PROFIT(Q)

Lowest at USD -39.9 MM

NET PROFIT(Q)

Lowest at USD -39.83 MM

EPS(Q)

Lowest at USD -5.71

Here's what is working for Karyopharm Therapeutics, Inc.

Operating Cash Flow

Highest at USD -75.37 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Debtors Turnover Ratio

Highest at 5.13 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -0.22% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Karyopharm Therapeutics, Inc.

Interest

At USD 12.62 MM has Grown at 14.63%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Interest

Highest at USD 12.62 MM

in the last five periods and Increased by 14.63% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Pre-Tax Profit

Lowest at USD -39.9 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Pre-Tax Profit

At USD -39.9 MM has Fallen at -28.07%

over average net sales of the previous four periods of USD -31.15 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -39.83 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Net Profit

At USD -39.83 MM has Fallen at -27.85%

over average net sales of the previous four periods of USD -31.16 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -5.71

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Cash and Eqv

Lowest at USD 109.62 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents